These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29523487)

  • 21. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
    Murín J; Pernický M; Kiňová S
    Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P; Rye KA
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk.
    Barter PJ; Rye KA
    Cardiol Clin; 2018 May; 36(2):299-310. PubMed ID: 29609759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesteryl ester transfer protein in type 2 diabetes mellitus.
    Yagyu H; Nagashima S; Takahashi M; Miyamoto M; Okada K; Osuga J; Ishibashi S
    Endocr J; 2012; 59(12):1077-84. PubMed ID: 22850130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week.
    Armitage J; Holmes MV; Preiss D
    J Am Coll Cardiol; 2019 Feb; 73(4):477-487. PubMed ID: 30704580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
    Lüscher TF; Taddei S; Kaski JC; Jukema JW; Kallend D; Münzel T; Kastelein JJ; Deanfield JE;
    Eur Heart J; 2012 Apr; 33(7):857-65. PubMed ID: 22345126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fasting cholesteryl ester transfer protein concentration is independently associated with the postprandial decrease in high-density lipoprotein cholesterol concentration after fat-rich meals: the Hoorn prandial study.
    Alssema M; El-Harchaoui K; Schindhelm RK; Diamant M; Nijpels G; Kostense PJ; Teerlink T; Heine RJ; Dallinga-Thie GM; Kuivenhoven JA; Dekker JM; Scheffer PG
    Metabolism; 2010 Jun; 59(6):854-60. PubMed ID: 20005542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine.
    Carrilho AJ; Medina WL; Nakandakare ER; Quintão EC
    Clin Pharmacol Ther; 1997 Jul; 62(1):82-8. PubMed ID: 9246022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
    Mantlo NB; Escribano A
    J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CETP inhibition in cardiovascular risk management: a critical appraisal.
    Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
    Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.
    Sofat R; Hingorani AD; Smeeth L; Humphries SE; Talmud PJ; Cooper J; Shah T; Sandhu MS; Ricketts SL; Boekholdt SM; Wareham N; Khaw KT; Kumari M; Kivimaki M; Marmot M; Asselbergs FW; van der Harst P; Dullaart RP; Navis G; van Veldhuisen DJ; Van Gilst WH; Thompson JF; McCaskie P; Palmer LJ; Arca M; Quagliarini F; Gaudio C; Cambien F; Nicaud V; Poirer O; Gudnason V; Isaacs A; Witteman JC; van Duijn CM; Pencina M; Vasan RS; D'Agostino RB; Ordovas J; Li TY; Kakko S; Kauma H; Savolainen MJ; Kesäniemi YA; Sandhofer A; Paulweber B; Sorli JV; Goto A; Yokoyama S; Okumura K; Horne BD; Packard C; Freeman D; Ford I; Sattar N; McCormack V; Lawlor DA; Ebrahim S; Smith GD; Kastelein JJ; Deanfield J; Casas JP
    Circulation; 2010 Jan; 121(1):52-62. PubMed ID: 20026784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
    Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trials and Tribulations of CETP Inhibitors.
    Tall AR; Rader DJ
    Circ Res; 2018 Jan; 122(1):106-112. PubMed ID: 29018035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dalcetrapib , a cholesteryl ester transfer protein modulator.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1427-32. PubMed ID: 22725099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dalcetrapib: a review of Phase II data.
    Robinson JG
    Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The therapeutic potential of CETP inhibitors: a patent review.
    Wang X; Li W; Hao L; Xie H; Hao C; Liu C; Li W; Xiong X; Zhao D
    Expert Opin Ther Pat; 2018 Apr; 28(4):331-340. PubMed ID: 29424255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
    Gotto AM; Kher U; Chatterjee MS; Liu Y; Li XS; Vaidya S; Cannon CP; Brinton EA; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):543-9. PubMed ID: 24737712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
    Doggrell SA
    Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.